ArticlemSphere2021
Shedding of Viable Virus in Asymptomatic SARS-CoV-2 Carriers.
Article in mSphere, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- A Systematic Review of Prolonged SARS-CoV-2 Shedding in Immunocompromised Persons.Influenza and other respiratory viruses · 2025Pooled it
- Transmission of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) from pre and asymptomatic infected individuals: a systematic review.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022Pooled it
- Modeling the risk of airborne transmission of respiratory viruses in microgravity.NPJ microgravity · 2026Article
- Human metapneumovirus (hMPV) in 2025: emerging trends and insights from community and hospital-based respiratory panel analyses-a comprehensive review.Virology journal · 2025Review
- Article
- The ratio between SARS-CoV-2 RNA viral load and culturable viral titre differs depending on the stage of infection: a case study of household transmission in an adult male.Access microbiology · 2025Article
- Recently reported SARS-CoV-2 genomes suggested to be intermediate between the two early main lineages are instead likely derived.Virus evolution · 2025Article
- A T-Cell-Derived 3-Gene Signature Distinguishes SARS-CoV-2 from Common Respiratory Viruses.Viruses · 2024Article
- COVID-19: An overview on possible transmission ways, sampling matrices and diagnosis.BioImpacts : BI · 2024Review
- Analytical sensitivity of COVID-19 rapid antigen tests: A case for a robust reference standard.Talanta open · 2023Article
- Oligosymptomatic long-term carriers of SARS-CoV-2 display impaired innate resistance but increased high-affinity anti-spike antibodies.iScience · 2023Article
- The role of immune activation and antigen persistence in acute and long COVID.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2023Review
- Transmission of SARS-CoV-2 Associated with Cruise Ship Travel: A Systematic Review.Tropical medicine and infectious disease · 2022Review
- The molecular epidemiology of multiple zoonotic origins of SARS-CoV-2.Science (New York, N.Y.) · 2022Article
- SARS-CoV-2 Amino Acid Mutations Detection in Greek Patients Infected in the First Wave of the Pandemic.Microorganisms · 2022Article
- Effect of cannabidiol on apoptosis and cellular interferon and interferon-stimulated gene responses to the SARS-CoV-2 genes ORF8, ORF10 and M protein.Life sciences · 2022Article
- Hide and seek in a pandemic: review of SARS-CoV-2 infection and sequelae in children.Experimental physiology · 2022Review
- Investigation of SARS-CoV-2 presence on environmental surfaces and waste in healthcare and non-healthcare facilities.Environmental challenges (Amsterdam, Netherlands) · 2022Article
- Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19.Frontiers in bioengineering and biotechnology · 2022Review
- Considerations for the Safe Operation of Schools During the Coronavirus Pandemic.Frontiers in public health · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Information regarding the infectivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in asymptomatic carriers is scarce. In order to determine the duration of infectivity and its correlation with reverse transcription-PCR (RT-PCR) results and time since initial positive PCR test in this population, we evaluated SARS-CoV-2 cell infectivity in nasopharyngeal samples longitudinally obtained from asymptomatic carriers who disembarked from a cruise ship during a COVID-19 outbreak. Of 166 nasopharyngeal samples collected from 39 asymptomatic carriers every 48 h until two consecutive negative PCR test results were obtained, SARS-CoV-2 was successfully isolated from 9 PCR-positive samples which were obtained from 7 persons (18%; 7/39). Viable viruses were isolated predominantly within 7 days after the initial positive PCR test, except for one person who shed viable virus until day 15. The median crossing point (Cp) value of RT-PCR of culture-positive samples was 24.6 (interquartile range [IQR], 20.4 to 25.8; range, 17.9 to 30.3), and Cp values were significantly associated with isolation of viable virus (odds ratio, 0.496; 95% confidence interval [CI], 0.329 to 0.747;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.